This is open-labe randomized multicenter comparative Phase III study conducted in 12 medical facilities. The objective of the study is to evaluate efficacy and safety of the drug JCBC00101, capsules in the setting of pathogenetic and symptomatic therapy as compared to standard therapy in outpatients with COVID-19.

Upon signing the informed consent form and screening, 240 eligible outpatients with mild or moderate COVID-19 were randomized at a 1:1 ratio to receive either molnupiravir capsules, 800 mg, 2 times a day with 12 ±2 hours interval for 5 days, or SOC

Inclusion Criteria:

1. Availability of PIS Informed Consent Form signed and dated by a patient.

2. Male and female subjects aged 18 to 80 inclusive as of the time of signing the PIS Informed Consent Form.

3. Confirmed COVID-19 at screening stage: positive for SARS-CoV-2 RNA laboratory test with nucleic acid amplification techniques (NAAT) or SARS-CoV-2 antigen with immunochromatographic assay.

   SARS-CoV-2 test results obtained up to 5 days prior to randomization may be taken into account upon availability of supporting documentation.

4. Mild or moderate SARS-CoV-2 induced infection.

5. At least one of the following COVID-19 symptoms as of the time of screening and randomization: nasal congestion or rhinitis; sore throat; dyspnoea or respiratory distress on exertion; cough; tiredness; pain in muscles or throughout the body; headache; chills; fever (body temperature >38 ⁰С); nausea; vomiting; diarrhea; anosmia; ageusia.

6. Disease onset (first symptom) within not more than 5 days prior to randomization .

7. The patient agrees and is able to take oral drug products.

8. Patient's consent to use reliable contraception methods during the entire study and for 3 weeks after the end of the study. Reliable contraception methods are: sexual abstinence, the use of a condom combined with a spermicidal agent.

Female subjects incapable of bearing children (history: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as male subjects with infertility or a history of vasectomy may participate in the study.

Exclusion Criteria:

1. Hypersensitivity to the study drug components.
2. Favipiravir intake within 7 days prior to screening.
3. Necessity to use drugs included the prohibited therapy list.
4. Hospitalization necessity or expected hospitalization due to COVID-19 within 48 hrs after randomization.
5. Severe and extremely severe disease signs as of the time of screening.
6. Vaccination within less than 4 weeks prior to screening.
7. Possible or confirmed moderate COVID-19 within 6 months prior to screening.
8. Possible or confirmed history of severe or very severe COVID-19.
9. Patients with chronic kidney disease on dialysis or with GFR < 30 mL/min as of the time of screening.
10. History of HIV, syphilis, HBV and/or HCV.
11. Blood components transfusion within 7 days prior to screening.
12. Alcohol, pharmacological and/or drug dependence (history and/or at the time of screening).
13. Schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorder (history or suspected) at the time of screening.
14. Any history data that may complicate, in the opinion of the investigator, interpretation of the study results or create additional risk for the patient due to his/her participation in the study.
15. Unwillingness or inability of a patient to comply with the Protocol procedures (in the opinion of the investigator).
16. Pregnant or lactating women, or women planning a pregnancy.
17. Participation in another clinical study within 3 months prior to enrollment in the present study.
18. Other conditions investigator considers as preventing the patient from inclusion in the study.